Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups

Blood (2024) 144 (Supplement 1): 675.

https://doi.org/10.1182/blood-2024-201736

Published: 2024

Journal Articles

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Blood blood.2024025746.

https://doi.org/10.1182/blood.2024025746

Published: 2024

Includes: Supplemental data

Journal Articles

Primary and Secondary Plasma Cell Leukemia Risk Stratification By Circulating Plasma Cells

Andrew Y Li, Farin Kamangar, Noa G. Holtzman, Aaron P. Rapoport, Mehmet H. Kocoglu, Djordje Atanackovic, Zeba N Singh, Sameer Sawhney, Ying S Zou, Ashraf Z. Badros

Blood (2023) 142 (Supplement 1): 6627.

https://doi.org/10.1182/blood-2023-178314

Published: 2023

Journal Articles

Phase I/II Study of Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone (BelCyd) in Relapsed/Refractory Multiple Myeloma

Ashraf Z. Badros, Thea Nash, Christopher Lawrance, Brandon Tittle, Sunita Philip, Sarah Sunshine, Wuqaas Munir, Xiaoxuan Fan, Christina Ide, Djordje Atanackovic

Blood (2023) 142 (Supplement 1): 6723.

https://doi.org/10.1182/blood-2023-182254

Published: 2023

Journal Articles

In Vivo Anti-BCMA CAR T-Cell Expansion Kinetics Correlate with Early IMWG Response in RRMM: A Single Institution Study with Comparative Analysis of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel

Mehmet H. Kocoglu, Aaron P. Rapoport, Tim Luetkens, Etse Gebru, Destiny Omili, Jean A. Yared, Nancy M. Hardy, Soren M Bentzen, Ashraf Z. Badros, Djordje Atanackovic

Blood (2023) 142 (Supplement 1): 1973.

https://doi.org/10.1182/blood-2023-189468

Published: 2023

Journal Articles

An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne A. Efebera, Brandi Reeves, Tanya M. Wildes, Sarah A. Holstein, Larry D. Anderson, Jr., Ashraf Z. Badros, Leyla O. Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees

Blood (2022) 140 (Supplement 1): 10154–10156.

https://doi.org/10.1182/blood-2022-162473

Published: 2022

Journal Articles

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Shaji K Kumar, Melissa Alsina, Betsy Laplant, Ashraf Z. Badros, Al-Ola Abdallah, Rafat Abonour, Erik J Asmus, Binod Dhakal, Cara A. Rosenbaum, Daniel Egan, Manisha Bhutani, Andrzej Jakubowiak, Brian G.M. Durie

Blood (2022) 140 (Supplement 1): 1830–1832.

https://doi.org/10.1182/blood-2022-168930

Published: 2022

Journal Articles

Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial

Sagar Lonial, Al-Ola Abdallah, Faiz Anwer, Ashraf Z. Badros, Manisha Bhutani, Abdullah Khan, Brea Lipe, Albert Oriol, Darrell White, Michael Amatangelo, Kexin Jin, Mark Masin, Vi Nguyen, Alpesh Amin, Paulo Maciag, Niels WCJ Van De Donk

Blood (2022) 140 (Supplement 1): 4398–4400.

https://doi.org/10.1182/blood-2022-158180

Published: 2022

Journal Articles

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Blood (2022) 140 (Supplement 1): 7301–7303.

https://doi.org/10.1182/blood-2022-164877

Published: 2022

Journal Articles

Impact of Induction Treatment on Stem Cell Collection: A COVID Related Study

Brad Rybinski, Ashraf Z. Badros, Aaron P. Rapoport, Mehmet Hakan Kocoglu

Blood (2021) 138 (Supplement 1): 4848.

https://doi.org/10.1182/blood-2021-149812

Published: 2021

Journal Articles

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Blood (2021) 138 (Supplement 1): 3793.

https://doi.org/10.1182/blood-2021-146003

Published: 2021

Journal Articles

Quantitative Cross-Sectional Analyses of Quality-of-Life Outcomes Related to Race, Sex, Age, and Clinical Stage Among Multiple Myeloma Patients at an Urban Center

Meghan Luhowy, Katrina Binion, Tiffany Warfield, Rebecca Bosley, Elizabeth Krauss, Ashraf Z. Badros

Blood (2021) 138 (Supplement 1): 5014.

https://doi.org/10.1182/blood-2021-149827

Published: 2021

Journal Articles

Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial

Blood (2021) 138 (Supplement 1): 162.

https://doi.org/10.1182/blood-2021-147704

Published: 2021

Journal Articles

Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?

Blood (2021) 138 (Supplement 1): 2746.

https://doi.org/10.1182/blood-2021-152681

Published: 2021

Journal Articles

Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

Blood (2021) 138 (Supplement 1): 1634.

https://doi.org/10.1182/blood-2021-146324

Published: 2021

Journal Articles

Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Response to Immunotherapy in Patients with High-Risk Smoldering Myeloma

Blood (2021) 138 (Supplement 1): 330.

https://doi.org/10.1182/blood-2021-147623

Published: 2021

Journal Articles

Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)

Rakesh Popat, Aikaterini Kazantzi, MD, Asim Farooq, MD, Praneetha Thulasi, MD, Sagar Lonial, MD FACP, Andrzej Jakubowiak, MD PhD, Ashraf Z. Badros, MD, Bennie H. Jeng, MD, Joanna Opalinska, MD, January Baron, MS, Trisha Piontek, BSN, Julie Byrne, PhD, Lynsey Womersley, MSc, Ira Gupta, MD, Simona Degli Esposti, MD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-139315

Published: 2020

Journal Articles

Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study

Holger W Auner, MD PhD, Maria Gavriatopoulou, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Meletios A Dimopoulos, Irina Kryachok, Professor, Halyna Pylypenko, MD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Maria Mateos, MD PhD, Michele Cavo, Anita A. Joshi, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-137303

Published: 2020

Journal Articles

Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

Blood (2020) 136 (Supplement 1): 50–52.

https://doi.org/10.1182/blood-2020-137574

Published: 2020

Journal Articles

Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Ajay Nooka, MDMPH, Hans C. Lee, MD, Ashraf Z. Badros, MD, Peter Voorhees, MD, Malin Hultcrantz, MD PhD, Lionel Karlin, MD, Bertrand Arnulf, MD, Paul G. Richardson, MD, Eric Zhi, PhD, January Baron, MS, Trisha Piontek, BSN, Eric Lewis, MD, Joanna Opalinska, MD PhD, Ira Gupta, MD, Adam D. Cohen, MD, Sagar Lonial, MD FACP

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-139687

Published: 2020

NARROW

Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Primary and Secondary Plasma Cell Leukemia Risk Stratification By Circulating Plasma Cells

Phase I/II Study of Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone (BelCyd) in Relapsed/Refractory Multiple Myeloma

In Vivo Anti-BCMA CAR T-Cell Expansion Kinetics Correlate with Early IMWG Response in RRMM: A Single Institution Study with Comparative Analysis of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel

An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Impact of Induction Treatment on Stem Cell Collection: A COVID Related Study

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Quantitative Cross-Sectional Analyses of Quality-of-Life Outcomes Related to Race, Sex, Age, and Clinical Stage Among Multiple Myeloma Patients at an Urban Center

Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial

Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?

Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Response to Immunotherapy in Patients with High-Risk Smoldering Myeloma

Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)

Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study

Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only